Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
NCT04456998 is registered in ClinicalTrials.gov with GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 12, 2020
- Completion date
- November 1, 2022
- Enrollment
- 86 (actual)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.
pulmonary artery hypertension